These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25710689)

  • 1. [Assessment of the effectiveness and safety of Sativex® in compassionate use].
    Cimas-Hernando I; Pato-Pato A; Lorenzo-González JR; Rodríguez-Constenla I
    Rev Neurol; 2015 Mar; 60(5):202-6. PubMed ID: 25710689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
    Carotenuto A; Iodice R; Petracca M; Inglese M; Cerillo I; Cocozza S; Saiote C; Brunetti A; Tedeschi E; Manganelli F; Orefice G
    Acta Neurol Scand; 2017 Apr; 135(4):442-448. PubMed ID: 27500463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Collin C; Ehler E; Waberzinek G; Alsindi Z; Davies P; Powell K; Notcutt W; O'Leary C; Ratcliffe S; Nováková I; Zapletalova O; Piková J; Ambler Z
    Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
    Wade D
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):9-14. PubMed ID: 22509986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    Leocani L; Nuara A; Houdayer E; Schiavetti I; Del Carro U; Amadio S; Straffi L; Rossi P; Martinelli V; Vila C; Sormani MP; Comi G
    J Neurol; 2015 Nov; 262(11):2520-7. PubMed ID: 26289497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
    Sastre-Garriga J; Vila C; Clissold S; Montalban X
    Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
    Arroyo R; Vila C; Dechant KL
    J Comp Eff Res; 2014 Jul; 3(4):435-44. PubMed ID: 25275238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
    Lu L; Pearce H; Roome C; Shearer J; Lang IA; Stein K
    Pharmacoeconomics; 2012 Dec; 30(12):1157-71. PubMed ID: 23072659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
    Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
    Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
    Slof J; Gras A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):439-41. PubMed ID: 22681512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
    Slof J; Ruiz L; Vila C
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):379-91. PubMed ID: 25771713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP
    Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
    Oreja-Guevara C
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the management of MS symptoms: real-life evidence.
    Trojano M
    Neurodegener Dis Manag; 2015; 5(6 Suppl):19-21. PubMed ID: 26611267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
    Wade DT; Collin C; Stott C; Duncombe P
    Mult Scler; 2010 Jun; 16(6):707-14. PubMed ID: 20558502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.